EBS Technologies | Updates

By Team EBS Technologies

The Patient Registry Is an Important Asset for EBS Technologies


Dear Companists,

One of the major objectives we want to achieve with the help of the capital raised on Companisto is the creation of a patient registry. Since this is one of the most important steps in our company's further development at the clinical level, we would like to explain it to you in more detail here.


What Is a Patient Registry?

A patient registry is an online database where the most important results of preliminary and follow-up patient examinations in regard to specific illnesses are stored. In this database, data are stored in the context of a forward study, i.e., results are entered immediately before and after therapy. This approach is meant to encourage physicians to collaborate, to prevent superfluous and duplicate entries, and to ensure transparency of all therapy results.

In most cases, such a registry is created with the help of external institutes, which are responsible both for programming the registry and for evaluating the statistical data. Thus, all data are collected and analyzed independently of the manufacturer.


What Will the EBS Patient Registry Look Like?


Collecting therapy results also has significant advantages for EBS Technologies. First, the EBS patient registry will help us increase credibility of the EBS therapy method. While clinical trials have already proven that the EBS therapy method works, new and up-to-date results are invaluable for the method's future. Additional data provide additional evidence for specific illnesses so that it is possible to make more qualified efficacy projections.

Moreover, a large volume of data is the most important prerequisite for coverage of the costs by health insurance companies.

To achieve this objective, we want all physicians in our therapy centers all over Germany (and, at a later time, all over Europe and the world) to use the EBS patient registry so that there will be almost no delay in the collection of therapy results. Furthermore, this evaluation of clinical success is intended to take place over an extended period of at least 3 years.

However, before a comprehensive international registry has been successfully set up, many things have to be considered and organized, which may take up to one year. This includes, but is not limited to, programming the register, agreeing on the contents with physicians, having the register evaluated by an ethics committee, integrating an external statistical evaluation institute, etc.

Finally, the creation of such a complex database is a very expensive task, which is why we are still glad about each euro raised via Companisto that helps us make progress on this necessary project.

See you next week!

The EBS Technologies Team


Only registered Companists can comment. Please log in to leave a comment.


Investments in startups and growth companies offer great opportunities, but they are risk investments. In the worst case, the entire investment amount may be lost. Consequently, investments in startups or growth companies are unsuitable for retirement plans. However, there is no obligation to make further contributions. Investors can minimize their risk by diversifying the amount they invest in startups and growth companies and not investing the entire amount in one startup or growth company. Professional investors often follow this strategy because it causes the risk to be distributed among several investments. In this way, successful investments can balance other less successful investments.

The shares of the investors on Companisto are subordinated profit-participating loans (partiarische Nachrangdarlehen). Such loans are shares in a business with similar characteristics as equity. If the company becomes insolvent or is liquidated, the claims of the investors (Companists) – just like those of all other shareholders of the company – will be satisfied from the assets in the insolvency or the assets in liquidation only after the claims of all other external creditors have been satisfied. Thus, Companists are treated like any other shareholder of the company during insolvency or liquidation proceedings.

The company information published on the Companisto website is provided solely by the companies. The projections made by the companies do not guarantee successful development of the company in the future. Consequently, investments in startups and growth companies are suitable only for those investors who can cope with the risk of a total loss of the capital invested. Investors make their own independent investment decisions and bear all risks themselves.

The investments are provided and issued by the individual companies. Companisto is neither the provider nor the issuer of the investments, but solely the internet service platform.

€ 258,825




3.67 %

Share Offered

Please note
The acquisition of this asset involves considerable risks and can lead to the complete loss of the assets used. The expected yield is not guaranteed and may turn out to be lower.
Contact Us
If you have any questions about investing on Companisto, please contact our service team:

Toll-free phone number for investors calling from Germany:
0800 - 100 267 0

Companisto investors hotline:
+49(0)30 - 346 491 493

We are available Monday through Friday between 9 a.m. – 7 p.m.

For companies
Apply for financing Investment Model FAQ for Companies
Investor Support
Please register in order to see the complete profile of EBS Technologies.
Already registered?    Log in